Sunday, April 13, 2008

Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types

AMG 386 Preclinical Data Suggests Greater Reduction in Tumor Growth when Angiopoietin 1/2 and VEGF Pathways are Both Inhibited

SAN DIEGO – April 13, 2008 – Amgen (NASDAQ:AMGN), today announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386, a recombinant Fc-peptide fusion protein (peptibody) designed to bind angiopoietins 1 and 2, thereby inhibiting Tie2 dependent stimulation of endothelial cells, was combined with either of two vascular endothelial growth factor (VEGF) inhibitors—bevacizumab or motesanib diphosphate (AMG 706)—compared with either treatment alone (p less than 0.05). Angiopoietins, together with VEGFs, are key cytokines that regulate neovascularization. The results of preclinical studies that investigated the growth of human colon tumor cells in this combination were presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Friday, April 11, 2008

Amgen-Teach for America Summit to Focus on Strategies for Advancing Math and Science Education

More Than 300 Leading Thinkers, Teach For America Corps Members and Alumni Expected at Second Annual Gathering

PALO ALTO, Calif., April 11, 2008 – How will we improve math and science education in our country? What steps can we take to lay an early foundation for student success in these subject areas? How can we incorporate technology into the classroom to increase student achievement?

These are some of the questions on tap for the Amgen-Teach For America Mathematics and Science Summit, to be held April 12 at Stanford University in Palo Alto, Calif. The second annual event will bring together Teach For America corps members, alumni, and leaders from a variety of sectors to consider key strategies for advancing mathematics and science education, inspire greater involvement in support of math and science education, and maximize connections to professional resources and opportunities.

Read the rest of this entry

Posted in Philanthropy, Press Releases

Tuesday, April 08, 2008

Amgen Statement on Romiplostim PDUFA Date

THOUSAND OAKS, Calif. – April 8, 2008 – Amgen Inc. (NASDAQ:AMGN) today issued the following statement on the Prescription Drug User Fee Act (PDUFA) date for romiplostim.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Thursday, April 03, 2008

Amgen's Oncology Pipeline Data Highlighted at Upcoming Scientific Meeting

Five Investigational Compounds from Robust Ongoing Clinical Trials Program Target Novel Cancer Pathways

THOUSAND OAKS, Calif.—April 3, 2008—Amgen (NASDAQ: AMGN) today announced that results from several preclinical and clinical trials investigating cancer treatment will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2008 in San Diego between April 12-16, 2008. Data will be presented on pipeline compounds: AMG 102, AMG 386, AMG 479, AMG 655 and motesanib diphosphate (AMG 706).

Read the rest of this entry

Posted in Press Releases, Pipeline News

Thursday, April 03, 2008

Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women

Overall Incidence of Adverse Events Similar Between Denosumab and Placebo Groups

THOUSAND OAKS, Calif.—April 2, 2008—Amgen (NASDAQ: AMGN) today announced the publication of results from its 24-month, 332-patient Phase 3 pivotal study in women with early and late stage postmenopausal osteoporosis in the Journal of Clinical Endocrinology and Metabolism.

Read the rest of this entry

Posted in Press Releases, Pipeline News